Based on the available data, these drugs are great as adjunct OSA treatments, which include CPAP therapy for most patients. Tirzepatide significantly improved OSA outcomes, with concomitant reduction in body weight, compared with placebo in the SURMOUNT-OSA study
in one study, they saw improvements at 4 weeks, and even more at 8 weeks, so continuing for at least 2 months is advisable to judge benefit
A study by Forsling et al
There are three likely waves in the near future for small-molecule GLP-1RAs
In recent years, the role of GPX3 in oxidative stress has been reported, for example: GPX3 can inhibit the expression of HIF1- by regulating ROS, thereby inhibiting the growth of melanoma cells (Yi et al., 2019)
You want a more structured return to activity rather than trying to figure it out on your own